These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17084284)

  • 1. Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis.
    Yan SF; Harja E; Andrassy M; Fujita T; Schmidt AM
    J Am Coll Cardiol; 2006 Nov; 48(9 Suppl 1):A47-55. PubMed ID: 17084284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury.
    Andrassy M; Belov D; Harja E; Zou YS; Leitges M; Katus HA; Nawroth PP; Yan SD; Schmidt AM; Yan SF
    Circ Res; 2005 Mar; 96(4):476-83. PubMed ID: 15662033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress on the drug therapy for diabetic microangiopathies: PKCbeta inhibitor].
    Koya D; Kashiwagi A
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():139-43. PubMed ID: 15999697
    [No Abstract]   [Full Text] [Related]  

  • 6. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
    Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
    Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the MEK/ERK pathway reduces microglial activation and interleukin-1-beta expression in spinal cord ischemia/reperfusion injury in rats.
    Lu K; Cho CL; Liang CL; Chen SD; Liliang PC; Wang SY; Chen HJ
    J Thorac Cardiovasc Surg; 2007 Apr; 133(4):934-41. PubMed ID: 17382630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early growth response-1 in cardiovascular pathobiology.
    Khachigian LM
    Circ Res; 2006 Feb; 98(2):186-91. PubMed ID: 16456111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury.
    Malabanan KP; Kanellakis P; Bobik A; Khachigian LM
    Circ Res; 2008 Aug; 103(4):378-87. PubMed ID: 18617696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.
    Liu SL; Li YH; Shi GY; Tang SH; Jiang SJ; Huang CW; Liu PY; Hong JS; Wu HL
    Cardiovasc Res; 2009 Apr; 82(1):161-9. PubMed ID: 19189960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
    Yang YB; Yang YX; Su B; Tang YL; Zhu BY; Hu ZW; Li GY; Li YJ; Liao DF
    Eur J Pharmacol; 2007 Sep; 570(1-3):125-34. PubMed ID: 17628533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protein kinase C beta-Inhibitor ruboxistaurin].
    Musch A
    Med Monatsschr Pharm; 2005 Aug; 28(8):292-3. PubMed ID: 16128544
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
    Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
    [No Abstract]   [Full Text] [Related]  

  • 15. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes.
    Tchaikovski V; Olieslagers S; Böhmer FD; Waltenberger J
    Circulation; 2009 Jul; 120(2):150-9. PubMed ID: 19564559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angio-associated migratory cell protein and smooth muscle cell migration in development of restenosis and atherosclerosis.
    Holvoet P; Sinnaeve P
    J Am Coll Cardiol; 2008 Jul; 52(4):312-4. PubMed ID: 18634988
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury.
    Khan R; Agrotis A; Bobik A
    Cardiovasc Res; 2007 May; 74(2):223-34. PubMed ID: 17349984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial expression of a dominant-negative form of Daxx decreases infarct size and attenuates apoptosis in an in vivo mouse model of ischemia/reperfusion injury.
    Roubille F; Combes S; Leal-Sanchez J; Barrère C; Cransac F; Sportouch-Dukhan C; Gahide G; Serre I; Kupfer E; Richard S; Hueber AO; Nargeot J; Piot C; Barrère-Lemaire S
    Circulation; 2007 Dec; 116(23):2709-17. PubMed ID: 18025529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.